In addition, receptor tyrosine kinase-dependent ERK1 and ERK2 activation following PI3K/AKT/mTOR inhibition have also been described in preclinical models of HER2-positive breast tumours [23,42]. This evidence concerns the gene ERBB2 and breast neoplasm.